Work for Aileron Therapeutics, Inc.?

Claim Your Profile

Aileron Therapeutics, Inc. Logo Image

Aileron Therapeutics, Inc.

Aileron Therapeutics, Inc. Banner Image

About Aileron Therapeutics, Inc.

11-50 Employees
Based in Watertown, Massachusetts

Aileron Therapeutics (NASDAQ:ALRN) is a clinical-stage biopharmaceutical company that is discovering and developing novel medicines to improve the outcomes and the quality of life of cancer patients by targeting high-value and historically undruggable targets using their proprietary platform of stabilized cell-permeating peptides. Their lead product candidate, ALRN-6924, is a cell-permeating peptide that mimics the p53 tumor suppressor protein to disrupt p53’s interactions with its endogenous inhibitors, MDMX and MDM2. Their focus at Aileron is the clinical development of ALRN-6924 to protect cancer patients against chemotherapy-induced toxicities, a novel concept they call “chemoprotection.”

NASDAQ (See More NASDAQ Companies)
Biotechnology (See More Biotechnology Companies)
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol